Differentiation of human embryonic stem cells
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to increase the expression of NGN3 and NKX6.1 in populations of cells expressing markers characteristic of the pancreatic endocrine lineage.
1. A method for increasing the expression of NGN3 and NKX6.1 in a population of pancreatic endoderm cells comprising the steps of:
a) obtaining human embryonic stem cells,
b) differentiating the human embryonic stem cells into definitive endoderm cells by treating the human embryonic stem cells with a medium supplemented with a TGF-β receptor agonist,
c) differentiating the definitive endoderm cells into pancreatic endoderm cells by culturing the definitive endoderm cells in a medium supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, HA-1004, PP2, PP1, SB-203580, SB-202190, Tyrphostin 25, Tyrphostin AG1478, Tyrphostin 46, GW 5074, hydroxy-2-naphthalenylmethylphosphonic acid, AG490, Y27632, and ML-7, and
d) differentiating the pancreatic endoderm cells into pancreatic endocrine cells by culturing the pancreatic endoderm cells with noggin, wherein the method increases the expression of NGN3 and NKX6.1 in pancreatic endoderm cells compared to pancreatic endoderm cells differentiated from definitive endoderm cells that are not treated with the compound.
2. The method of claim 1 , wherein the medium used to differentiate the pancreatic endoderm cells is supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, HA-1004, PP2, PP1, SB-203580, SB-202190, Tyrphostin 25, Tyrphostin AG1478, Tyrphostin 46, and GW 5074.
3. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, and HA-1004.
4. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with PP2 or PP1.
5. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with SB-203580 or SB-202190.
6. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with Tyrphostin 25, Tyrphostin AG1478, or Tyrphostin 46.
7. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with GW 5074.
8. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with hydroxy-2-naphthalenylmethylphosphonic acid.
9. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with AG490.
10. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with Y27632.
11. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into pancreatic endoderm lineage cells comprises culturing the definitive endoderm cells in medium supplemented with ML-7.
12. A method for increasing the expression of NGN3 and NKX6.1 in a population of pancreatic endoderm cells comprising the steps of:
a) obtaining and differentiating definitive endoderm cells into pancreatic endoderm cells by culturing the definitive endoderm cells in a medium supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, HA-1004, PP2, PP1, SB-203580, SB-202190, Tyrphostin 25, Tyrphostin AG1478, Tyrphostin 46, GW 5074, hydroxy-2-naphthalenylmethylphosphonic acid, AG490, Y27632, and ML-7, and
b) differentiating the pancreatic endoderm cells into pancreatic endocrine cells, wherein the method increases the expression of NGN3 and NKX6.1 in pancreatic endoderm cells compared to pancreatic endoderm cells differentiated from definitive endoderm cells that are not treated with the compound.
13. The method of claim 12 , wherein the method comprises culturing the definitive endoderm in a medium supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, HA-1004, PP2, PP1, SB-203580, SB-202190, Tyrphostin 25, Tyrphostin AG1478, Tyrphostin 46, and GW 5074.
14. The method of claim 12 , wherein the method comprises culturing the definitive endoderm cells in a medium supplemented with a compound selected from the group consisting of H-9, H-89, GF 109203X, and HA-1004.
15. The method of claim 12 , wherein the method comprises culturing the definitive endoderm cells in a medium supplemented with PP2 or PP1.
16. The method of claim 12 , wherein the method comprises culturing the definitive endoderm cells in a medium supplemented with SB-203580 or SB-202190.
17. The method of claim 12 , wherein the method comprises culturing the definitive endoderm cells in a medium supplemented with Tyrphostin 25, Tyrphostin AG1478, or Tyrphostin 46.
18. The method of claim 12 , wherein the method comprises culturing the definitive endoderm cells in a medium supplemented with GW 5074, hydroxy-2-naphthalenylmethylphosphonic acid or AG490.
19. The method of claim 12 , wherein the method comprises culturing the definitive endoderm cells in a medium supplemented with Y27632 or ML-7.